13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • AGEN 1884

    Acronym: 

    AGEN 1884

    ACTRN/NCT /ethics: 

    NCT03411473

    Scientific title: 

    Study of AGEN1884 with Pembrolizumab in 1L NSLC

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II Tumour Stream Non-small lung cancer
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date 2017-10-04
    Molecular Target Anticipated End Date 2021-05-01
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Non-small lung cancer
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date 2017-10-04
    Anticipated End Date 2021-05-01

    Trial Summary

    This is a Phase IIa, open-label study, of AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations. The study consists in two phases: Safety Run-in Phase Efficacy Phase Subjects will be enrolled in a "3+3" Safety Run-in followed by enrollment completing the efficacy cohort. Two different dose levels of AGEN1884 may be tested in combination with the approved pembrolizumab treatment for this indication (until disease progression, unacceptable toxicity, or up to a maximum of 24 months). Each subject will stay on the dose level assigned at trial entry.

    Lay Summary

    Study of AGEN1884 with Pembrolizumab in 1L NSLC

    Sponsor / Cooperative group

    Agenus Inc.

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Chris Karapetis Recruitment on Hold